Synairgen’s H1 2023 results re-established management’s commitment to progressing its lead respiratory anti-viral asset SNG001 through clinical development. The results of the Phase III SPRINTER trial and the US Government’s ACTIV-2 trial produced valuable data suggesting SNG001 has potential to reduce the risk of disease progression, especially in more severely affected and higher risk patient populations. The company is currently undertaking patient identification activities to select patients ....
